Citations

Clear

499 citation(s) found for "Tracy, PB".

Abstract 15: Association of topoisomerase II expression and cancer-specific death in patients with surgically-resected clear cell renal cell carcinoma.
Serie, Dan, Hilton, Tracy, Parasramka, Mansi, Eckel‐Passow, Jeanette E. , Cheville, John C. , Leibovich, Bradley C. , Parker, Alexander S. , Joseph, Richard W.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 15-15

10.1158/1538-7445.am2013-15 Get It

Abstract PURPOSE: Despite the development of prognostic algorithms based on clinico-pathologic features, the ability to identify aggressive forms of clear cell renal cell carcinoma (ccRCC) remains suboptimal. Topoisomerase IIA (TOP2a) is a biomarker of DNA replication and a target for antineoplastic agents. Herein, we evaluate the association of TOP2a expression in ccRCC tumors with pathologic features of aggressiveness and risk of cancer-specific death. METHODS: We identified 947 patients who underwent nephrectomy to treat clinically localized ccRCC between 1/16/1990 and 9/27/2006. TOP2a expression was assessed using IHC and scored as number of positive cells per mm2. We evaluated TOP2a expression using a continuous variable and tertile categories. For associations with pathologic features we employed Kruskal-Wallis tests and for associations with cancer-specific survival we generated Cox proportional hazard regression models. RESULTS: Higher TOP2a expression is associated with later stage, higher grade and higher Mayo SSIGN score (all p < 0.001). The risk of death from RCC increases with increasing TOP2a expression (p trend < 0.0001). Compared to patients in the lowest tertile, those patients with tumors in the highest tertile of TOP2a expression were at increased risk of RCC death (HR=2.31 95% CI 1.64-3.25; p<0.0001). Interestingly, among those patients with low risk disease (SSIGN score 0-3; ∼95% 10 year survival), those with high TOP2a were at increased risk of RCC death (HR=3.09 95% CI 1.29-7.40; p =0.01). CONCLUSION: Higher TOP2a expression is associated with more aggressive pathologic features and increased risk of cancer-specific death among patients undergoing surgery for localized ccRCC. If confirmed, these data support further inquiry for TOP2a as a prognostic and predictive biomarker for ccRCC patients. Citation Format: Richard W. Joseph, Dan Serie, Tracy Hilton, Mansi Parasramka, Jeanette Eckel-Passow, John Cheville, Bradley C. Leibovich, Alexander S. Parker. Association of topoisomerase II expression and cancer-specific death in patients with surgically-resected clear cell renal cell carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 15. doi:10.1158/1538-7445.AM2013-15
Regionalization of pediatric anesthesia care: has the time come?
Harrison, Tracy E. , Engelhardt, Thomas , Flick, Randall P., Macfarlane, Fiona R.

Mayo Clinic

Pediatric Anesthesia | August 4, 2014 | Volume: 24 | Issue: 9 | Pages: 897-898

10.1111/pan.12432 | PMID 25092445 Get It

De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Hasserjian, Robert P. , Campigotto, Federico, Klepeis, Veronica, Fu, Bin , Wang, Sa A. , Bueso‐Ramos, Carlos E. , Cascio, Michael J. , Soderquist, Craig , Bagg, Adam , Yan, Jiong , Ochs, Rachel, Orazi, Attilio , Moore, Frank, Mahmoud, Amer, George, Tracy I. , Foucar, Kathryn , Odem, Jamie L., Booth, Cassie, Morice, William G. , Stone, Richard M. , Rogers, Heesun J. , Hsi, Eric D. , Morice, William George , DeAngelo, Daniel J. , Steensma, David P. , Neuberg, Donna , Arber, Daniel A. , Cascio, M J , George, Tracy I , Orazi, Attilio

Mayo Clinic

American Journal of Hematology | July 17, 2014 | Volume: 89 | Issue: 11 | Pages: No page available

10.1002/ajh.23808 | PMID 25042343 Get It

It is controversial whether acute myeloid leukemia (AML) patients with 20–29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10–19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4‐year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML. Am. J. Hematol. 89:E193–E199, 2014. © 2014 Wiley Periodicals, Inc.
Age-related ventricular–vascular coupling during acute inflammation in humans: Effect of physical activity
Lane, Abbi D., Kappus, Rebecca M. , Bunsawat, Kanokwan , Ranadive, Sushant M. , Yan, Huimin , Phillips, Shane A. , Baynard, Tracy , Woods, Jeffrey A. , Motl, Robert W. , Fernhall, Bo , Ranadive, Sushant

Mayo Clinic

European Journal of Preventive Cardiology | July 5, 2014 | Volume: 22 | Issue: 7 | Pages: 904-911

10.1177/2047487314542056 | PMID 24996847 Get It

A Causative Relationship Exists Between Eosinophils and the Development of Allergic Pulmonary Pathologies in the Mouse
Shen, Hua-Hao, Ochkur, Sergei I. , McGarry, Michael P. , Crosby, Jeffrey R., Hines, Edie M., Borchers, Michael T. , Wang, Huiying , Biechelle, Travis L., O'Neill, K.R. , Ansay, Tracy, Colbert, Dana, Cormier, Stephania A. , Justice, J. Paul, Lee, Nancy A., Lee, James J. , Shen, HuaHao H

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 170 | Issue: 6 | Pages: 3296-3305

10.4049/jimmunol.170.6.3296 | PMID 12626589 Get It

Abstract Asthma and mouse models of allergic respiratory inflammation are invariably associated with a pulmonary eosinophilia; however, this association has remained correlative. In this report, a causative relationship between eosinophils and allergen-provoked pathologies was established using eosinophil adoptive transfer. Eosinophils were transferred directly into the lungs of either naive or OVA-treated IL-5−/− mice. This strategy resulted in a pulmonary eosinophilia equivalent to that observed in OVA-treated wild-type animals. A concomitant consequence of this eosinophil transfer was an increase in Th2 bronchoalveolar lavage cytokine levels and the restoration of intracellular epithelial mucus in OVA-treated IL-5−/− mice equivalent to OVA-treated wild-type levels. Moreover, the transfer also resulted in the development of airway hyperresponsiveness. These pulmonary changes did not occur when eosinophils were transferred into naive IL-5−/− mice, eliminating nonspecific consequences of the eosinophil transfer as a possible explanation. Significantly, administration of OVA-treated IL-5−/− mice with GK1.5 (anti-CD4) Abs abolished the increases in mucus accumulation and airway hyperresponsiveness following adoptive transfer of eosinophils. Thus, CD4+ T cell-mediated inflammatory signals as well as signals derived from eosinophils are each necessary, yet alone insufficient, for the development of allergic pulmonary pathology. These data support an expanded view of T cell and eosinophil activities and suggest that eosinophil effector functions impinge directly on lung function.
Gq Signaling Is Required for Allergen-Induced Pulmonary Eosinophilia
Borchers, Michael T. , Justice, Paul J., Ansay, Tracy, Mancino, Valeria, McGarry, Michael P. , Crosby, Jeffrey R., Simon, Melvin I., Lee, Nancy A., Lee, James J.

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 168 | Issue: 7 | Pages: 3543-3549

10.4049/jimmunol.168.7.3543 | PMID 11907117 Get It

Abstract The complexity and magnitude of interactions leading to the selective infiltration of eosinophils in response to inhaled allergens are formidable obstacles to a larger understanding of the pulmonary pathology associated with allergic asthma. This study uses knockout mice to demonstrate a novel function for the heterotrimeric G protein, Gq, in the regulation of pulmonary eosinophil recruitment. In the absence of Gq signaling, eosinophils failed to accumulate in the lungs following allergen challenge. These studies demonstrate that the inhibition of eosinophil accumulation in the airways is attributed to the failure of hemopoietically derived cells to elaborate GM-CSF in the airways. The data suggest that activation of a Gq-coupled receptor(s) on resident leukocytes in the lung elicits expression of GM-CSF, which, in turn, is required for allergen-induced pulmonary eosinophilia, identifying a novel pathway of eosinophil-associated effector functions leading to pulmonary pathology in diseases such as asthma.
Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial
Heck, Christianne, King‐Stephens, David , Nair, Dileep , Jobst, Barbara C. , Barkley, Gregory L., Salanova, Vicenta , Gwinn, Ryder P. , Skidmore, Christopher , Ness, Paul C. Van, Bergey, Gregory K. , Park, Yong D., Miller, Ian , Geller, Eric B., Rutecki, Paul , Zimmerman, Richard S. , Spencer, David , Leiphart, James W., Wharen, Robert E. , Fessler, James, Fountain, Nathan B. , Eisenschenk, Stephan, Duckrow, Robert B., Hirsch, Lawrence J. , Bazil, Carl W., O’Donovan, Cormac A. , Sun, Felice T., Courtney, Tracy A., Seale, Cairn G. , Morrell, Martha J. , Massey, Andrew D. , Cole, Andrew J. , Smith, Michael C. F. , Goldman, Alica M. , Edwards, Jonathan , Worrell, Gregory A. , Gross, Robert E. , Fountain, Nathan , Hirsch, Lawrence J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | February 24, 2014 | Volume: 55 | Issue: 3 | Pages: 432-441

10.1111/epi.12534 | PMID 24621228 Get It

Summary Objective To demonstrate the safety and effectiveness of responsive stimulation at the seizure focus as an adjunctive therapy to reduce the frequency of seizures in adults with medically intractable partial onset seizures arising from one or two seizure foci. Methods Randomized multicenter double‐blinded controlled trial of responsive focal cortical stimulation (RNS System). Subjects with medically intractable partial onset seizures from one or two foci were implanted, and 1 month postimplant were randomized 1:1 to active or sham stimulation. After the fifth postimplant month, all subjects received responsive stimulation in an open label period ( OLP ) to complete 2 years of postimplant follow‐up. Results All 191 subjects were randomized. The percent change in seizures at the end of the blinded period was −37.9% in the active and −17.3% in the sham stimulation group (p = 0.012, Generalized Estimating Equations). The median percent reduction in seizures in the OLP was 44% at 1 year and 53% at 2 years, which represents a progressive and significant improvement with time (p < 0.0001). The serious adverse event rate was not different between subjects receiving active and sham stimulation. Adverse events were consistent with the known risks of an implanted medical device, seizures, and of other epilepsy treatments. There were no adverse effects on neuropsychological function or mood. Significance Responsive stimulation to the seizure focus reduced the frequency of partial‐onset seizures acutely, showed improving seizure reduction over time, was well tolerated, and was acceptably safe. The RNS System provides an additional treatment option for patients with medically intractable partial‐onset seizures.
Abstract B12: An optimized molecular stool test for colorectal cancer screening: Evaluation of an automated analytic platform and logistic algorithm
Lidgard, Graham P. , Domanico, Michael J. , Bruinsma, Janelle J., Light, James, Oldham-Haltom, Rebecca, Fourrier, Keith D. , Allawi, Hatim T. , Yab, Tracy C. , Simonson, Julie A., Devens, Mary E., Heigh, Russell I., Ahlquist, David A. , Gagrat, Zubin D. , Berger, Barry M.

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: B12-B12

10.1158/1940-6207.prev-12-b12 Get It

Abstract We have demonstrated that colorectal cancer (CRC) and advanced pre-cancers can be detected non-invasively by a manual multi-target stool DNA-based test (sDNA-MT) comprising exfoliated DNA markers (methylated BMP3 and NDRG4, mutant KRAS (7 mutations, codons 12, 13), plus β-actin) and fecal hemoglobin (Hb) (Lidgard, Gastroenterology 2012;142(5);S-770). We now report the clinical performance of this sDNA-MT test using an optimized automated analytic platform and logistic algorithm. This platform could facilitate the routine performance of sDNA-MT for CRC screening by molecular diagnostics capable clinical laboratories. Method: Stool samples were collected from 1003 subjects at 36 study sites after informed consent and prior to colonoscopy bowel preparation from those presenting for average risk CRC screening (283) or surveillance (176) at 2 sites. From referred subjects with CRC, Advanced Adenoma (AA) or Sessile Serrate Adenoma ≥ 1 cm, (SSA) stool was collected at least 7 days post-colonoscopy and prior to surgery or chemo-radiation (135; 21 sites) and similarly for subjects with no neoplastic findings on colonoscopy (Neg) (409; 13 sites). The study population included: cases (207), 58% male, median age 65 yrs. (38-87), CRC (93), AA (84), SSA ≥ 1 cm (30) and controls (796), 42% male, median age 65 yrs. (50-84), Neg (641) and non-advanced adenomas (NA) (155). Stool sample collection and DNA isolation were previously described. Automated methylation, mutation and actin assays were performed with a Hamilton STARlet fluid handler (Hamilton Robotics, Reno NV), and QuARTS (Quantitative Allele-specific Real-time Target and Signal amplification) run on an ABI 7500 FastDx real time thermal cycler (Applied Biosystems, Foster City, CA). Fecal Hb (ng/ml buffer) analysis was performed by automated sandwich ELISA. A “Positive” or “Negative” result was determined with an algorithm that included the methylation and mutation results and a logistic regression score, which combines DNA marker results with Hb and actin results. Algorithm results exceeding a threshold were called “Positive”. The algorithm provided good discriminative ability, stability, sensitivity and specificity. Robustness was tested with computer simulations and statistical techniques (leave-one-out and 10-fold cross validation). Results: At a 90% nominal specificity, sDNA-MT sensitivity was 98% for CRC (91/93) [Stage: I, 95% (20/21), II, 100% (23/23), III 96% (26/27), IV 100% (7/7) and I-III combined 97% (69/71)], 57% (65/114) for precursors ≥1 cm (AA, SSA), and 86% (12/14) for precursors with high grade dysplasia. CRC patients were typically referred to colonoscopy for symptoms and test sensitivity may be elevated relative to that seen with screening. Conclusion: With this study using a novel automated sDNA-MT analytic platform with logistic algorithm, we corroborate our earlier findings using a manual process and demonstrate a platform that allows testing to be performed routinely by molecular diagnostic capable laboratories. The high sensitivity of sDNA-MT for CRC across all stages and for advanced precursors with high-grade dysplasia could lead to improved non-invasive CRC screening performance with wide accessibility to patients. A large multi-site pivotal CRC screening study (DeeP-C study clinicaltrials.gov, NCT01397747) to support such use is underway. Citation Format: Graham P. Lidgard, Michael J. Domanico, Janelle J. Bruinsma, James Light, Zubin D. Gagrat, Rebecca L. Oldham-Haltom, Keith D. Fourrier, Hatim Allawi, Tracy C. Yab, Julie A. Simonson, Mary Devens, Russell I. Heigh, David A. Ahlquist, Barry M. Berger. An optimized molecular stool test for colorectal cancer screening: Evaluation of an automated analytic platform and logistic algorithm. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B12.
Teaching Neuro Images : Dyspnea as a presenting manifestation of amyloid myopathy
Ghosh, Partha S. , Thaera, Greg M., Tracy, Jennifer A.

Mayo Clinic

Neurology | December 9, 2013 | Volume: 81 | Issue: 24 | Pages: No page available

10.1212/01.wnl.0000437300.51312.9e | PMID 24323446 Get It